• Search
  • Menu
Gore
  • Contact
  • Home
  • Products
  • Resource Library
  • News & Events
  • About Gore
  • Careers
  • Contact Us
  • Search
  • Resource Library

Application Note: Sodium Hydroxide (NaOH) Exposure Conditions for Successful Operation of GORE® Protein Capture Devices with Protein A for Drug Discovery Applications

Application Note: Sodium Hydroxide (NaOH) Exposure Conditions for Successful Operation of GORE<sup>®</sup> Protein Capture Devices with Protein A for Drug Discovery Applications

United States

Share: Mail Copy URL Twitter Linked In Facebook

This application note provides data to support sodium hydroxide (NaOH) exposure limits for the 1.0mL and 3.5mL GORE Protein Capture Devices (PROA101 and PROA102). The cycling protocol utilizing 0.5 molar (M) NaOH supports 50 purification cycles with minimal impact to purification yield, device capacity, or assessed purity.

View as PDF (350.26 KB)

Contact Us

Americas

+1 800 294 4673

+1 410 506 1715

Europe

+49 89 4612 3456

+800 4612 3456

All Other Inquiries

+1 800 294 4673

+1 410 506 1715

Contact by email

Related Products

Pharmaceutical & Biopharmaceutical

  • Affinity chromatography devices

Related Industries

  • Life Sciences
  • Pharmaceutical & Biopharmaceutical Industry

View all Industries

Pharmaceutical & Biopharmaceutical News & Events

Event

GORE PharmBIO’s Dr. William Barrett to speak at the 4th Annual Bioprocessing Summit Europe

March 16, 2021 - March 17, 2021

Join GORE PharmBIO’s Dr. William Barrett as he presents “Demonstrating Scalability of High Flow, High Binding Protein A Chromatography Membranes for Bioprocessing.”

Event

GORE PharmBIO’s Rob Gelissen to Speak at the 12th Global Drug Delivery & Formulation Virtual Summit 2021

March 15, 2021 - March 17, 2021

Join GORE PharmBIO’s Rob Gelissen, Business Development representative for Drug Delivery and Packaging for W.L. Gore & Associates’ PharmBIO Division on March as he presents “Silicone-Free Prefilled Syringe Packages for Sensitive Biologics and Ophthalmic injections.”
 

Press Release

ViaCyte and Gore Enter Clinical Phase Agreement Based on Novel Membrane Technology for PEC-Encap Product Candidate

Posted August 5, 2020

Clinical evaluation of PEC-Encap has resumed using sentinels created with the novel membrane; preclinical and initial clinical data suggest the novel membrane can mitigate the foreign body host response.

View All News & Events

  • Privacy Notice
  • Terms of Use

Copyright 2021 W. L. Gore & Associates, Inc.

Follow us:

  • LinkedIn
  • YouTube
  • Glassdoor
  • California Supply Chain Act / Human Trafficking Statement